Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-stratified Treatment of PTLD (PTLD-2)
NCT02042391Phase 2Completed
- Sponsor
- DIAKO Bremen
- Start
- Feb 2015
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by DIAKO Bremen. Started Feb 2015; status: completed.
02
Drugs
rituximab
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT02042391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02042391.